Manuel Pestana

List of Publications by Year
in descending order

121 papers	5,615 citations	257101 24 h-index	79541 73 g-index
121 all docs	121 docs citations	121 times ranked	5499 citing authors

#	Article	IF	Citations
1	Endothelial Dysfunction Is Associated with Cerebrovascular Events in Pre-Dialysis CKD Patients: A Prospective Study. Life, 2021, 11, 128.	1.1	8
2	Circulating Renalase as Predictor of Renal and Cardiovascular Outcomes in Pre-Dialysis CKD Patients: A 5-Year Prospective Cohort Study. Life, 2021, 11, 210.	1.1	3
3	Viral Clearance and Serological Response to SARS-CoV-2 in Kidney Transplant Recipients. Transplantation Proceedings, 2021, 53, 1180-1186.	0.3	10
4	Peritoneal Microbiome in End-Stage Renal Disease Patients and the Impact of Peritoneal Dialysis Therapy. Microorganisms, 2020, 8, 173.	1.6	16
5	Arteriolar C4d in IgA Nephropathy: A Cohort Study. American Journal of Kidney Diseases, 2020, 76, 669-678.	2.1	23
6	The microbiome in chronic kidney disease patients undergoing hemodialysis and peritoneal dialysis. Pharmacological Research, 2018, 130, 143-151.	3.1	43
7	Reactivation of Hepatitis B virus in kidney transplant recipients with previous clinically resolved infection: A single-center experience. Nefrologia, 2018, 38, 545-550.	0.2	9
8	SP388THE DECREASE IN PHOSPHATE INTAKE IMPROVES ENDOTHELIAL FUNCTION IN PRE-DIALYSIS CKD PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i477-i477.	0.4	0
9	An integrated program of extracorporeal membrane oxygenation (ECMO) assisted cardiopulmonary resuscitation and uncontrolled donation after circulatory determination of death in refractory cardiac arrest. Resuscitation, 2018, 133, 88-94.	1.3	30
10	Oral Colonization ofStaphylococcusSpecies in a Peritoneal Dialysis Population: A Possible Reservoir for PD-Related Infections?. Canadian Journal of Infectious Diseases and Medical Microbiology, 2018, 2018, 1-6.	0.7	10
11	Calcitriol Prevents Cardiovascular Repercussions in Puromycin Aminonucleoside-Induced Nephrotic Syndrome. BioMed Research International, 2018, 2018, 1-10.	0.9	2
12	Planning Vascular Access in Peritoneal Dialysisâ€"Defining High-Risk Patients. Peritoneal Dialysis International, 2018, 38, 271-277.	1.1	7
13	Phase Angle Predicts Arterial Stiffness and Vascular Calcification in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2017, 37, 451-457.	1.1	15
14	Parathyroidectomy in Persistent Post-transplantation Hyperparathyroidism â€" Single-center Experience. Transplantation Proceedings, 2017, 49, 795-798.	0.3	13
15	Oral Yeast Colonization and Fungal Infections in Peritoneal Dialysis Patients: A Pilot Study. Canadian Journal of Infectious Diseases and Medical Microbiology, 2017, 2017, 1-7.	0.7	4
16	The Role of the Gut Microbiome on Chronic Kidney Disease. Advances in Applied Microbiology, 2016, 96, 65-94.	1.3	86
17	Late Allograft Renal Vein Thrombosis Treated With Anticoagulation Alone: A Case Report. Transplantation Proceedings, 2016, 48, 3095-3098.	0.3	4
18	Asymptomatic Effluent Protozoa Colonization in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2016, 36, 566-569.	1.1	5

#	Article	IF	Citations
19	Cryptococcosis in Renal Transplant Recipients: A Single-Center Experience. Transplantation Proceedings, 2016, 48, 2289-2293.	0.3	12
20	Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients. Clinical Nephrology, 2016, 85 (2016), 135-141.	0.4	29
21	SP511PERITONEAL DIALYSIS: INFECTIOUS AGENTS OR NORMAL MICROBIOTA. Nephrology Dialysis Transplantation, 2015, 30, iii547-iii548.	0.4	0
22	Clinical value of natriuretic peptides in chronic kidney disease. Nefrologia, 2015, 35, 227-233.	0.2	26
23	Post-transplant Lymphoproliferative Disorder: A Single-Center Experience. Transplantation Proceedings, 2015, 47, 981-984.	0.3	10
24	SP321RENALASE, RENAL FUNCTION AND BIOMARKERS OF ENDOTHELIAL DYSFUNCTION IN CHRONIC KIDNEY DISEASE PATIENTS. Nephrology Dialysis Transplantation, 2015, 30, iii485-iii485.	0.4	0
25	Clinical value of natriuretic peptides in chronic kidney disease. Nefrologia, 2015, 35, 227-233.	0.2	10
26	Renalase regulates peripheral and central dopaminergic activities. American Journal of Physiology - Renal Physiology, 2015, 308, F84-F91.	1.3	16
27	Combined C4d and CD3 immunostaining predicts immunoglobulin (Ig)A nephropathy progression. Clinical and Experimental Immunology, 2015, 179, 354-361.	1.1	36
28	Plasma Renalase in Chronic Kidney Disease: Differences and Similarities between Humans and Rats. Current Hypertension Reviews, 2015, 10, 166-170.	0.5	8
29	Assessment of Renalase Activity on Catecholamines Degradation. Open Hypertension Journal, 2015, 7, 14-18.	0.8	4
30	Accelerated atherosclerosis after renal transplantation: an unsuspected cause of uncontrolled hypertension. International Journal of Nephrology and Renovascular Disease, 2014, 7, 295.	0.8	1
31	Ganciclovir-resistant cytomegalovirus infection in renal transplantation. CKJ: Clinical Kidney Journal, 2014, 7, 210-213.	1.4	5
32	Plasma and urine renalase levels and activity during the recovery of renal function in kidney transplant recipients. Experimental Biology and Medicine, 2014, 239, 502-508.	1.1	17
33	Bacteremia due to <scp>C</scp>ampylobacter in renal transplantation: a case report and review of literature. Transplant Infectious Disease, 2014, 16, 1007-1011.	0.7	14
34	Renal Transplantation in Human Immunodeficiency Virusâ€“Positive Patients: A Report of Four Cases. Transplantation Proceedings, 2014, 46, 1718-1722.	0.3	0
35	Endothelial function in patients with metabolic syndrome and erectile dysfunction: a question of Angiopoietin imbalance?. Andrology, 2013, 1, 541-548.	1.9	11
36	Intestinal and renal guanylin peptides system in hypertensive obese mice. Experimental Biology and Medicine, 2013, 238, 90-97.	1.1	5

#	Article	IF	Citations
37	Cost Analysis of Hemodialysis and Peritoneal Dialysis Access in Incident Dialysis Patients. Peritoneal Dialysis International, 2013, 33, 662-670.	1.1	27
38	Concerted Action of ANP and Dopamine D1-Receptor to Regulate Sodium Homeostasis in Nephrotic Syndrome. BioMed Research International, 2013, 2013, 1-8.	0.9	10
39	Renalase regulates renal dopamine and phosphate metabolism. American Journal of Physiology - Renal Physiology, 2013, 305, F839-F844.	1.3	24
40	Periodontal inflammation in renal transplant recipients receiving <scp>E</scp>verolimus or <scp>T</scp>acrolimus â€“ preliminary results. Oral Diseases, 2013, 19, 666-672.	1.5	11
41	Sodium-dependent modulation of systemic and urinary renalase expression and activity in the rat remnant kidney. Journal of Hypertension, 2013, 31, 543-553.	0.3	21
42	Letter on â€˜Sodium-dependent modulation of systemic and urinary renalase expression and activity in the rat remnant kidneyâ€™. Journal of Hypertension, 2013, 31, 1274-1275.	0.3	1
43	Blunted renal dopaminergic system in a mouse model of diet-induced obesity. Experimental Biology and Medicine, 2012, 237, 949-955.	1.1	9
44	Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus, 2012, 21, 1433-1443.	0.8	40
45	Renalase Lowers Ambulatory Blood Pressure by Metabolizing Circulating Adrenaline. Journal of the American Heart Association, 2012, 1, e002634.	1.6	92
46	Physical examination of dysfunctional arteriovenous fistulae by non-interventionalists: a skill worth teaching. Nephrology Dialysis Transplantation, 2012, 27, 1993-1996.	0.4	46
47	Effects of starting hemodialysis with an arteriovenous fistula or central venous catheter compared with peritoneal dialysis: a retrospective cohort study. BMC Nephrology, 2012, 13, 88.	0.8	37
48	Renalase deficiency aggravates ischemic myocardial damage. Kidney International, 2011, 79, 853-860.	2.6	130
49	Early-onset of disseminated cryptococcal infection in two renal transplant recipients. Clinical Nephrology, 2011, 75, 542-546.	0.4	6
50	Interaction between GÎ±12 and GÎ±13 protein subunits and dopamine receptors in renal proximal tubules. Hypertension Research, 2011, 34, 987-988.	1.5	0
51	Cinacalcet in the treatment of persistent hyperparathyroidism after kidney transplantation. Clinical Nephrology, 2011, 75, 263-268.	0.4	17
52	Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis. New England Journal of Medicine, 2011, 365, 1886-1895.	13.9	544
53	Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurinâ€free regimen. Clinical Transplantation, 2011, 25, E401-5.	0.8	8
54	Endovascular treatment of thrombosed dialysis fistulae. Catheterization and Cardiovascular Interventions, 2011, 77, 1065-1070.	0.7	9

#	Article	IF	Citations
55	Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, openâ€label, parallelâ€group clinical trial. Arthritis and Rheumatism, 2010, 62, 211-221.	6.7	139
56	Attenuation of toll-like receptor 2-mediated innate immune response in patients with alcoholic chronic liver disease. Liver International, 2010, 30, 1003-1011.	1.9	22
57	Cerebral coccidioidomycosis after renal transplantation in a non-endemic area. Transplant Infectious Disease, 2010, 12, 151-154.	0.7	22
58	Cardiac dysfunction in HgCl₂-induced nephrotic syndrome. Experimental Biology and Medicine, 2010, 235, 392-400.	1.1	2
59	Percutaneous Treatment of Thrombosed Arteriovenous Fistulas. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2245-2250.	2.2	15
60	Treatment of severe dialysis reactions with the AN69-ST membrane: biocompatibility does matter. CKJ: Clinical Kidney Journal, 2010, 3, 298-299.	1.4	0
61	Glycaemic control with insulin prevents the reduced renal dopamine D1 receptor expression and function in streptozotocin-induced diabetes. Nephrology Dialysis Transplantation, 2010, 25, 2945-2953.	0.4	18
62	Relationship Between Everolimus Blood Concentration Assessed Using the Innofluor Certican Fluorescence Polarization Immunoassay and the Architect i System Sirolimus Chemiluminescent Microparticle Immunoassay. Transplantation Proceedings, 2010, 42, 1867-1869.	0.3	11
63	Therapeutic implications of heparin-induced thrombocytopenia complicating acute hemodialysis. Clinical Nephrology, 2010, 73, 326-330.	0.4	6
64	Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. Journal of the American Society of Nephrology: JASN, 2009, 20, 1103-1112.	3.0	923
65	Mycobacterium gordonae urinary infection in a renal transplant recipient. Transplant Infectious Disease, 2009, 11, 253-256.	0.7	19
66	A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2009, 361, 2019-2032.	13.9	2,110
67	Renal dopaminergic system activity in rat remnant kidney up to twenty-six weeks after surgery. Life Sciences, 2009, 84, 409-414.	2.0	9
68	Local modulation of the natriuretic peptide system in the rat remnant kidney. Nephrology Dialysis Transplantation, 2009, 24, 1774-1782.	0.4	11
69	Attenuation of the cardiovascular and metabolic complications of obesity in CD14 knockout mice. Life Sciences, 2008, 83, 502-510.	2.0	67
70	Cardiac remodeling and dysfunction in nephrotic syndrome. Kidney International, 2007, 71, 1240-1248.	2.6	18
71	Renal Dopaminergic System Activity in Uninephrectomized Rats up to 26 Weeks after Surgery. American Journal of Nephrology, 2007, 27, 232-239.	1.4	10
72	Postrenal Transplantation Body Composition: Different Evolution Depending on Gender. , 2007, 17, 151-156.		7

#	Article	IF	Citations
73	Blunted renal dopaminergic system activity in HgCl2-induced membranous nephropathy. Life Sciences, 2006, 78, 1246-1255.	2.0	4
74	Jejunal dopamine and Na+,K+-ATPase activity in early chronic renal insufficiency. Nephrology, 2006, 11, 63-67.	0.7	3
75	Blunted renal dopaminergic system activity in puromycin aminonucleoside-induced nephrotic syndrome. Nephrology Dialysis Transplantation, 2006, 21, 314-323.	0.4	11
76	Prolonged use of an intracardiac catheter for dialysis in a patient with multiple venous access failure. Nephrology Dialysis Transplantation, 2006, 21, 2670-2671.	0.4	4
77	Combined use of plasmapheresis and antidigoxin antibodies in a patient with severe digoxin intoxication and acute renal failure. Nephrology Dialysis Transplantation, 2006, 22, 257-258.	0.4	10
78	Role of Chronic Inhibition of Dopamine-Metabolizing Enzymes in the Regulation of Renal Sodium and Phosphate Excretion in the Rat Remnant Kidney. Nephron Physiology, 2006, 103, p14-p24.	1.5	12
79	Body Composition Assessed by Impedance Changes Very Early with Declining Renal Graft Function. Nephron Physiology, 2006, 104, p115-p120.	1.5	6
80	Sequential body composition analysis by bioimpedance early post-kidney transplantation. Transplant International, 2005, 18, 541-547.	0.8	8
81	Humoral immune response after kidney transplantation is enhanced by acute rejection and urological obstruction and is down-regulated by mycophenolate mofetil treatment. Transplant International, 2005, 18, 1286-1291.	0.8	8
82	Salt sensitivity of blood pressure in patients with psoriasis on ciclosporin therapy. British Journal of Dermatology, 2005, 152, 773-776.	1.4	7
83	Jejunal Dopamine and Na⁺,K⁺-ATPase Activity in Nephrotic Syndrome. American Journal of Nephrology, 2005, 25, 382-392.	1.4	0
84	Renal Dopaminergic System Activity in the Rat Remnant Kidney. Nephron Experimental Nephrology, 2005, 99, e46-e55.	2.4	22
85	Nutritional Status and Body Composition Evolution in Early Postâ€“Renal Transplantation: Is There a Female Advantage?. Transplantation Proceedings, 2005, 37, 2765-2770.	0.3	9
86	Renal Dopamine and Salt Sensitivity of Blood Pressure in IgA Nephropathy. Kidney and Blood Pressure Research, 2004, 27, 78-87.	0.9	4
87	The effect of dietary sodium restriction on neurohumoral activity and renal dopaminergic response in patients with heart failure. European Journal of Heart Failure, 2004, 6, 593-599.	2.9	65
88	Bioimpedance analysis highlights changes in body composition at the early stages of impairment of kidney transplant function. , 2004, 14, 157-163.		5
89	Cyclosporine enhances salt sensitivity of body water composition as assessed by impedance among psoriatic patients with normal renal function. , 2004, 14, 226-232.		1
90	Differences in the renal dopaminergic system activity between Wistar rats from two suppliers. Acta Physiologica Scandinavica, 2003, 178, 83-89.	2.3	10

#	Article	IF	Citations
91	Cultures of Kidney Transplant Fine-Needle Aspiration Samples from Rejection-Free Patients Produce a Specific Antidonor Response Suppressive Factor. Nephron, 2002, 91, 637-645.	0.9	5
92	The renal dopaminergic system, neurohumoral activation, and sodium handling in heart failure. American Heart Journal, 2002, 143, 391-397.	1.2	14
93	Compared to mycophenolate mofetil, rapamycin induces significant changes on growth factors and growth factor receptors in the early days postkidney transplantation1. Transplantation, 2002, 73, 915-920.	0.5	27
94	Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. Clinical Science, 2001, 100, 557-566.	1.8	22
95	Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. Clinical Science, 2001, 100, 557.	1.8	12
96	sTNFRI AND sTNFRII SYNTHESIS BY FINE-NEEDLE ASPIRATION BIOPSY SAMPLE CULTURES IS SIGNIFICANTLY ASSOCIATED WITH ACUTE REJECTION IN KIDNEY TRANSPLANTATION1. Transplantation, 2001, 71, 1835-1839.	0.5	9
97	Hypertension in the elderly. International Urology and Nephrology, 2001, 33, 563-569.	0.6	9
98	Heart failure, aging, and renal synthesis of dopamine. American Journal of Kidney Diseases, 2001, 38, 502-509.	2.1	11
99	Microemulsion cyclosporin formulation, in contrast to the old formulation, widens the T lymphocyte subsets differences between stable and acute rejection of kidney transplants. Nephrology Dialysis Transplantation, 2001, 16, 1256-1261.	0.4	10
100	Renal synthesis of dopamine in asymptomatic post-infarction left ventricular systolic dysfunction. Clinical Science, 2000, 99, 195-200.	1.8	7
101	Renal synthesis of dopamine in asymptomatic post-infarction left ventricular systolic dysfunction. Clinical Science, 2000, 99, 195.	1.8	4
102	SALT INTAKE AND SENSITIVITY OF INTESTINAL AND RENAL NA+-K+ATPase TO INHIBITION BY DOPAMINE IN SPONTANEOUS HYPERTENSIVE AND WISTAR-KYOTO RATS. Clinical and Experimental Hypertension, 2000, 22, 455-469.	0.5	26
103	RENAL DOPAMINERGIC MECHANISMS IN RENAL PARENCHYMAL DISEASES, HYPERTENSION, AND HEART FAILURE. Clinical and Experimental Hypertension, 2000, 22, 251-268.	0.5	12
104	Aging, High Salt Intake, and Renal Dopaminergic Activity in Fischer 344 Rats. Hypertension, 1999, 34, 666-672.	1.3	63
105	Kidney graft-infiltrating cells synthesize significantly higher amounts of prostaglandin e2 pre and during acute rejection. Transplantation Proceedings, 1999, 31, 306-307.	0.3	5
106	Acute Hypotensive, Natriuretic, and Hormonal Effects of Nifedipine in Salt-Sensitive and Salt-Resistant Black Normotensive and Hypertensive Subjects. Journal of Cardiovascular Pharmacology, 1999, 34, 346-353.	0.8	14
107	Evidence for the involvement of Pâ€glycoprotein on the extrusion of taken up L â€DOPA in cyclosporine A treated LLCâ€PK 1 cells. British Journal of Pharmacology, 1998, 123, 13-22.	2.7	10
108	Reduced Urinary Excretion of Dopamine and Metabolites in Chronic Renal Parenchymal Disease. Kidney and Blood Pressure Research, 1998, 21, 59-65.	0.9	26

#	Article	IF	Citations
109	Renal dopaminergic system in nephrotic syndrome and after remission. Nephrology Dialysis Transplantation, 1998, 13, 2559-2562.	0.4	2
110	Assessment of renal dopaminergic system activity during the recovery of renal function in human kidney transplant recipients. Nephrology Dialysis Transplantation, 1997, 12, 2667-2672.	0.4	12
111	Antagonistic actions of renal dopamine and 5â€hydroxytryptamine: endogenous 5â€hydroxytryptamine, 5â€HT_{1A} receptors and antinatriuresis during high sodium intake. British Journal of Pharmacology, 1996, 117, 1193-1198.	2.7	13
112	High sodium intake increases the urinary excretion of L-3,4-dihydroxyphenylalanine but fails to alter the urinary excretion of dopamine and amine metabolites in wistar rats. General Pharmacology, 1996, 27, 1421-1427.	0.7	10
113	Studies on the Nature of the Antagonistic Actions of Dopamine and 5-Hydroxytryptamine in Renal Tissues. Hypertension Research, 1995, 18, S47-S51.	1.5	12
114	Assessment of renal dopaminergic system activity during cyclosporine A administration in the rat. British Journal of Pharmacology, 1995, 115, 1349-1358.	2.7	26
115	Ontogeny of the cell outward dopamine transporter in canine renal tissues. Fundamental and Clinical Pharmacology, 1995, 9, 255-262.	1.0	4
116	Assessment of renal dopaminergic system activity in the nitric oxideâ€deprived hypertensive rat model. British Journal of Pharmacology, 1995, 114, 1403-1413.	2.7	54
117	Outflow of dopamine and noradrenaline originating from l-DOPA and in rat renal tissues. General Pharmacology, 1994, 25, 879-885.	0.7	1
118	The renal handling of dopamine originating from <scp>l</scp>â€DOPA and Î³â€glutamylâ€<scp>l</scp>â€DOPA. British Journal of Pharmacology, 1994, 112, 417-422.	2.7	15
119	Effect of type A and B monoamine oxidase selective inhibition by Ro 41â€“1049 and Ro 19â€“6327 on dopamine outflow in rat kidney slices. British Journal of Pharmacology, 1994, 113, 1269-1274.	2.7	19
120	A comparative study on the synthesis of dopamine in the human, dog and rat kidney. Acta Physiologica Scandinavica, 1993, 148, 347-351.	2.3	11
121	Deamination of newlyâ€formed dopamine in rat renal tissues. British Journal of Pharmacology, 1991, 102, 778-782.	2.7	28